Nanobiotix S.A. (EPA:NANO)
6.93
+0.45 (6.94%)
Aug 13, 2025, 5:39 PM CET
Endeavor Group Holdings Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue
-7.19M
Revenue Growth
-119.86%
P/S Ratio
-46.19
Revenue / Employee
-66.57K
Employees
108
Market Cap
332.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 27.24B |
Sanofi | 45.74B |
Sartorius Stedim Biotech | 2.90B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 7.14B |
Ipsen | 3.76B |
ABIVAX Société Anonyme | 10.59M |
Virbac | 1.40B |
Nanobiotix News
- 5 weeks ago - NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference - GlobeNewsWire
- 3 months ago - Nanobiotix Provides First Quarter 2025 Operational and Financial Update - GlobeNewsWire
- 3 months ago - Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 3 months ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ... - GuruFocus
- 3 months ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call - GlobeNewsWire
- 4 months ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha